King & Spalding is advising Arbor Pharmaceuticals, a portfolio company of KKR, in its acquisition by Azurity Pharmaceuticals, a portfolio company of NovaQuest. The transaction is expected to close at the end of 2021, subject to customary closing conditions, including regulatory approvals.
Arbor Pharmaceuticals is a specialty pharmaceutical company which markets prescription products for the cardiovascular, hospital, neuroscience and pediatric markets.
Azurity Pharmaceuticals is a specialty pharmaceutical company focusing on the needs of patients requiring customized, user-friendly drug formulations.
More information can be found here.
The King & Spalding deal team is led by Rahul Patel and John Anderson, and includes Nik Patel and Umbar Malik.